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Abstract: Recently, we demonstrated that the natural cytokinin nucleosides N6-isopentenyladenosine
(iPR) and N6-benzyladenosine (BAPR) exert a potent and selective antiviral effect on the replication
of human enterovirus 71. In order to further characterize the antiviral profile of this class
of compounds, we generated a series of fluorinated derivatives of BAPR and evaluated their
activity on the replication of human enterovirus 71 in a cytopathic effect (CPE) reduction assay.
The monofluorination of the BAPR-phenyl group changed the selectivity index (SI) slightly because
of the concomitant high cell toxicity. Interestingly, the incorporation of a second fluorine atom resulted
in a dramatic improvement of selectivity. Moreover, N6-trifluoromethylbenzyladenosine derivatives
(9–11) exhibited also a very interesting profile, with low cytotoxicity observed. In particular, the
analogue N6-(3-trifluoromethylbenzyl)-adenosine (10) with a four-fold gain in potency as compared
to BAPR and the best SI in the class represents a promising candidate for further development.
Keywords: fluorinated N6-benzyladenosines; synthesis and antiviral activity; SAR; enterovirus 71
1. Introduction
For many years, natural products (NPs) have been a leading source for the majority of the
approved drugs, and their structures are a valuable source of inspiration for medicinal chemists [1].
Interestingly, only 36% of the new chemical entities discovered between 1981 and 2010 were developed
without inspiration from a natural product [2].
Among natural products, the development of nucleosides is by far the most fruitful field of
investigation. About one hundred drugs derive from nucleoside structures: the vast majority of
them were developed as antiviral drugs, and a consistent proportion as antitumor drugs. Natural
nucleosides are isolated from DNA, RNA, nucleotides, and coenzymes of various natural sources.
Nowadays, the nucleoside library consists of about 550 compounds, and is a promising pool for the
development of new biologically active compounds [3–5].
N6-Modified purine nucleosides (cytokinin nucleosides) are an important group of biologically
active natural compounds with a unique spectrum of biological activities [3]. Cytokinin nucleosides
contain a hydrophilic ribofuranose moiety and a purine heterocyclic scaffold modified with a
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hydrophobic residue at the N6 position. tRNA contains N6-isopentenyladenosine and some related
nucleosides [6,7]. N6-Substituted adenosines are naturally present in plants [8–10] and bacteria [11].
In 2008, Arita and co-workers found that N6-benzyladenosine (BAPR) exhibited a pronounced
antiviral activity against the replication of human enterovirus 71 (EV71) [12]. EV71 is a non-enveloped,
single-stranded, positive-sense RNA virus belonging to the Enterovirus genus within the Picornaviridae
family. EV71 commonly causes hand-, foot-, and mouth disease (HFMD), a mild and self-limiting
illness mostly affecting children under the age of five. In some patients, EV71 has been associated
with severe neurological complications including encephalitis, aseptic meningitis, and acute flaccid
paralysis [13–15]. EV71 is prevalent worldwide, but most of the large outbreaks of neurotropic EV71
have occurred in the Pacific-Asia area [15–17]. However, in recent years, such epidemic tracts have
been reported also in America and in Europe [15,17]. The World Health Organization has placed EV71
as one of the next biggest worldwide threats to public health, especially to young children, due to the
lack of effective antiviral treatments [18,19].
Recently, we showed that, similarly to BAPR, two other naturally occurring plant cytokinin
nucleosides, namely N6-isopentenyladenosine and N6-furfuryladenosine (kinetin riboside), possessed
a potent and selective antiviral effect on EV71 [20,21]. Unfortunately, these compounds were rather
cytotoxic, with CC50 values in the low micromolar range (4–8 µM). We were able to improve the
selectivity of this group of compounds by modifying the size and the nature of the linker. In particular,
a modified BAPR with a two-to-three atom-long linker had a very pronounced antiviral activity, and
a 50-fold improvement of the selectivity index (SI) as result of a lower cytotoxicity [21].
The introduction of fluorine in order to improve the pharmacological properties of a drug is
a modern trend in medicinal chemistry. Currently, there are about 200 fluorinated drugs on the market
(~20% of all pharmaceuticals), with even higher figures for agrochemicals (up to 30%) [22,23]. Therefore,
in the present study, we report on the modification of natural BAPR by the substitution in the phenyl
ring with fluoro-, difluoro-, and trifluorometyl groups to evaluate the eventual improvement in the
antiviral profile of these fluorinated compounds in the context of EV71 replication (Figure 1).
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is hardly available. Using this methodology, several hundred N6-substituted adenosines have been
synthesized in one of our laboratories.
The traditional approach for the preparation of N6-alkylated or N6-arylated adenosines is the
substitution of the chlorine atom in commercially available 6-chloropurine riboside with alkyl-
or arylamines [26,27]. 6-Chloropurine riboside can be readily prepared by the deacetylation of
2′,3′,5′-tri-O-acetyl-6-chloropurine riboside [28].
To simplify the separation procedure, we used 2′,3′,5′-tri-O-acetyl-6-chloropurine riboside directly
in the substitution reactions. The acetyl groups are completely preserved in the reaction with aniline,
and the protected intermediate can be isolated by silica gel chromatography and characterized.
After the removal of the acetyl groups by ammonolysis, N6-phenyladenosine was obtained in overall
high yield [21]. On the other hand, the reaction of 2′,3′,5′-tri-O-acetyl-6-chloropurine riboside with
benzylamines was accompanied by the formation of by-products due to the partial removal of the
protective groups, which complicated the chromatographic control of the reaction, and required a large
excess of amines for the full conversion of the starting compound. Therefore, we decided to study
the stability of different O-acyl groups to select the one optimal for our purposes. The results of the
O-deacylation experiments of 2′,3′,5′-tri-O-acylinosine are summarized in Table 1.
Table 1. Stability of O-acyl protecting groups under different deblocking conditions.
Substrate O-Deacylation Conditions, 20 ◦C a t 1
2
. h Complete O-Deacylation, h
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Table 2. Antiviral effect of N6-substituted adenosines on the replication of the EV71 strain BrCr in
RD cells.
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Overall, the incorporation of fluoro- and trifluoromethyl groups significantly improved the
selectivity index of BAPR (Table 2). In particular, the monofluorination of the phenyl group
(compounds 5–7) slightly changed the SI because of the concomitant cytotoxicity of such compounds.
Surprisingly, the incorporati n of a second fluorine atom resulted in substanti l improvement
over the selectivity. In particular, compound 8 presented an EC50 comparable to BAPR with a
dramatic reduction of cell toxcity: from a CC50 of 13.3 ± 3.7 µM for the monofluorinated analogu
to a CC50 higher than 250 µM for the difluorinate counterpart. We wanted also to assess the
effect f a trifluorome hyl group on the phenyl ring of BAPR on EV71 replication. Co pounds
9, 10 and 11 did ot sh w a y cytotoxicity at th highest concentr tion ested, and th analogue
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N6-(3-trifluoromethylbenzyl)-adenosine (compound 10) exhibited also a four-fold improvement in
potency as compared to BAPR.
Previous reports showed that the halogenation (and, in particular, the addition of I or Cl atoms) on
a BAPR scaffold increased its selectivity by reducing the cell toxicity in cancer cell lines [26,30]. In line
with these findings, we observed that the gain in selectivity in our model was mostly due to a decreased
cell toxicity. In particular, only the analogues containing two fluorine or a trifluoromethyl group
dramatically improved the cytotoxicity. In spite of our interest in understanding compound-driven cell
toxicity, addressing this question was beyond our scientific scope. Future works on the optimization of
this class of analogues may shed light on the mechanism of action and their metabolization within an
infected cell.
Altogether, our data revealed that the introduction of at least two fluorine atoms or a
trifluoromethyl group on the phenyl ring of BAPR dramatically improved its selectivity by reducing
the cytotoxicity, and in case of compound 10, also by increasing the potency.
3. Materials and Methods
3.1. General
The solvents and materials were reagent grade and were used without additional purification.
Column chromatography was performed on silica gel (Kieselgel 60 Merck, Germany, 0.063–0.200 mm).
TLC was performed on an Alugram SIL G/UV254 (Macherey-Nagel, Düren, Germany) with UV
visualization. The melting points were determined with Electrothermal Melting Point Apparatus
IA6301 and are uncorrected. The 1H and 13C (with complete proton decoupling) NMR spectra were
recorded on a Bruker (Karlsruhe, Germany) AMX 400 NMR instrument at 303 K. The 1H-NMR-spectra
were recorded at 400 MHz and the 13C-NMR-spectra at 100 MHz. The chemical shifts in ppm were
measured relative to the residual solvent signals as internal standards (CDCl3, 1H: 7.26 ppm, 13C:
77.1 ppm; DMSO-d6, 1H: 2.50 ppm, 13C: 39.5 ppm). Spin-spin coupling constants (J) are given in Hz.
The high resolution mass spectra (HRMS) were registered on a Bruker Daltonics (Manning Park,
Billerica, MA, USA) micrOTOF-Q II instrument using electrospray ionization (ESI). The measurements
were done in positive ion mode. Interface capillary voltage: 4500 V; mass range from m/z 50 to
3000; external calibration (Electrospray Calibrant Solution, Fluka); nebulizer pressure: 0.4 Bar; flow
rate: 3 µL/min; dry gas: nitrogen (4 L/min); interface temperature: 200 ◦C. Samples were injected
into the mass spectrometer chamber from the Agilent 1260 HPLC system equipped with an Agilent
(Santa Clara, CA, USA) Poroshell 120 EC-C18 (3.0 × 50 mm; 2.7 µm) column: the flow rate was
200 µL/min; and the samples were injected from the acetonitrile–water (1:1) solution and eluted in
a linear gradient of acetonitrile concentrations (50→100%).
3.2. 9-(2,3,5-Tri-O-isobutyroyl-β-D-ribofuranosyl)-6-chloropurine (4)
Isobutyric anhydride (5.6 mL, 33.8 mmol) was added in portions to a suspension of 3 g (11.2 mmol)
of inosine in 18 mL of dry pyridine. The reaction mixture was stirred for 24 h at room temperature,
and then evaporated in vacuum. The residue was diluted with the mixture ethanol:water (50 mL), and
the suspension was filtered. The resulting powder was washed with the mixture ethanol:water (50 mL)
and dried in a vacuum dessicator over phosphorous pentoxide for 2 days. The yield was 5 g (93%) of
2′,3′,5′-tri-O-isobutyroylinosine as a white powder. Rf 0.39 (CH2Cl2:EtOH—98:2). 1H-NMR (400 MHz,
CDCl3): δ = 1.23–1.12 (m, 18H, Me-i-Bu), 2.66–2.50 (m, 3H, CH-i-Bu), 4.40 (d, 2H, J5′4′ = 3.7 Hz, H5
′),
4.45 (dt, 1H, J4′5′ = 3.7 Hz, J4′3′ = 4.6 Hz, H4
′), 5.60 (dd, 1H, J3′4′ = 4.6 Hz, J3′2′ = 5.4 Hz, H3′), 5.84 (dd,
1H, J2′3′ = 5.4 Hz, J2′1′ = 5.3 Hz, H2
′), 6.18 (d, 1H, J1′2′ = 5.3 Hz, H1′), 8.21 (br s, 2H, H2, H8 Hyp), 12.99
(br s, 1H, NH Hyp).
The compound 2′,3′,5′-tri-O-isobutyroylinosine (2.9 g, 6.05 mmol) was then dissolved in 30 mL of a
DMF:dichloroethane (1:15) mixture, and thionyl chloride (1.14 mL, 15.7 mmol) was added dropwise to
the mixture under intensive stirring. After stirring at 65 ◦C for 15 min, the reaction mixture was diluted
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with dichloromethane (60 mL) and washed successively with 10% sodium bicarbonate (4 × 50 mL)
and water (2 × 50 mL). The organic layer was separated, dried over anhydrous Na2SO4, filtered, and
evaporated in a vacuum. The residue was purified by column chromatography on silica gel (200 mL).
The column was washed with dichloromethane (200 mL). The product was eluted with the system
CH2Cl2:EtOH—96:4. The yield was 2.8 g (93%) as a slightly yellow syrup. Rf 0.52 (CH2Cl2:EtOH—98:2).
1H-NMR (400 MHz, CDCl3): δ = 1.09–1.23 (m, 18H, Me-i-Bu), 2.49–2.69 (m, 3H, CH-i-Bu), 4.40 (d,
2H, J5′ ,4′ = 3.7 Hz, H5
′), 4.27 (dd, 1H, J4′ ,5′ = 3.7 Hz, J4′ ,3′ = 4.5 Hz, H4′), 5.63 (dd, 1H, J3′ ,2′ = 5.3 Hz,
J4′ ,3′ = 4.5 Hz, H3
′), 5.89 (t, 1H, J2′ ,3′ = 5.3 Hz, J2′ ,1′ = 5.3 Hz, H2′), 6.22 (d, 1H, J1′ ,2′ = 5.3 Hz, H1′), 8.30
(s, 1H, H2), 8.76 (s, 1H, H8). 13C-NMR (100 MHz, CDCl3): δ = 18.77, 18.85, 18.93, 18.99, 19.01, 19.11
(CH3-i-Bu), 33.80, 33.92, 34.05 (CH-i-Bu), 63.05 (C5′), 70.55 (C3′), 73.46 (C2′), 81.12 (C4′), 87.10 (C1′),
132.40 (C6), 143.57 (C5), 151.42 (C8), 151.73 (C4), 152.44 (C2), 175.51, 175.71, 176.57 (C=O). HRMS: m/z
[M + H]+ calculated C22H30ClN4O7+ 497.1798, found 497.1798.
3.3. N6-(2-Fluorobenzyl)adenosine (5)
A mixture of 4 (200 mg, 0.4 mmol) and 2-fluorobenzylamine (0.091 mL, 0.8 mmol) was dissolved
in MeCN (3 mL), and then DIPEA (0.14 mL, 0.8 mmol) was added in one portion. The solution
was stirred at 70 ◦C. The reaction was monitored by TLC (CH2Cl2:EtOH—99.5:0.5). After 22 h,
the reaction mixture was evaporated in a vacuum and the residue was diluted with methylene
chloride (30 mL) and washed with water (2 × 15 mL). The organic layer was separated, dried over
anhydrous Na2SO4, and evaporated in a vacuum. The residue was purified by column chromatography
on silica gel. The product was eluted with CH2Cl2:EtOH—99:1. The yield was 208 mg (89%) of
N6-(2-fluorobenzyl)-2′,3′,5′-tri-O-isobutyroyladenosine as a syrup. Rf 0.6 (CH2Cl2:EtOH—99.5:0.5).
1H-NMR (400 MHz, DMSO-d6): δ = 1.0–1.2 (m, 18H, Me-i-Bu), 2.51–2.66 (m, 3H, CH-i-Bu), 4.35–4.41 (m,
2H, H5′), 4.27 (ddd, 1H, J4′ ,5′ = 6.1 Hz, H4′), 4.76 (br s, 2H, CH2), 5.75 (dd, 1H, J3′ ,2′ = 5.4 Hz, H3′), 6.03
(dd, 1H, J2′ ,3′ = 5.4 Hz, J2′ ,1′ = 4.9 Hz, H2
′), 6.21 (d, 1H, J1′ ,2′ = 4.9 Hz, H1′), 7.11 (td, 1H, 3J5-6 = 7.5 Hz,
3J5-4 = 7.5 Hz, 4J5-3 = 1.0 Hz, 5H-2-F-Ph), 7.16 (ddd, 1H, 3JH-F = 8.2 Hz, 3J3-4 = 8.8 Hz, 4J3-5 = 1.0 Hz,
3H-2-F-Ph), 7.28 (dddd, 1H, 4JH-F = 5.5 Hz, 3J4-3 = 8.8 Hz, 3J4-5= 7.5 Hz, 4J4-6 = 1.6 Hz, 4H-2-F-Ph), 7.32
(ddd, 1H, 4JH-F = 7.5 Hz, 3J6-5 = 7.5 Hz, 4J6-4 = 1.6 Hz, 6H-2-F-Ph), 7.23 (s, 1H, H2 Ade), 8.36 (s, 1H, H8
Ade), 8.42 (1H, NH).
The resulting N6-(2-fluorobenzyl)-2′,3′,5′-tri-O-isobutyroyladenosine (206 mg, 0.352 mmol) was
treated with 8 M MeNH2 in EtOH solution (4.5 mL). After 2 days, the mixture was evaporated in
a vacuum and the residue was purified by column chromatography on silica gel. The column was
washed with CH2Cl2:EtOH—95:5, and then eluted with CH2Cl2:EtOH—90:10 to give 5 as a white
powder. The yield was 118 mg (79% for two steps). Rf 0.15 (CH2Cl2:EtOH—95:5). m.p. 194–195 ◦C.
1H-NMR (400 MHz, DMSO-d6): δ = 3.55 (ddd, 1H, J5′b,5′a = −12.0 Hz, J5′b,4′ = 3.4 Hz, J5′b,OH = 6.9 Hz,
H5′b), 3.68 (ddd, 1H, J5′a,5′b = −12.0 Hz, J5′a,4′ = 3.4 Hz, J5′a,OH = 4.7 Hz, H5′a), 3.96 (q, 1H, J4′ ,5′b = 3.4,
J4′ ,5′a = 3.4 Hz, J4′ ,3′ = 3.4 Hz, H4
′), 4.15 (ddd, 1H, J3′ ,4′ = 3.4 Hz, J3′ ,2′ = 4.9 Hz, J3′ ,OH = 4.7 Hz, H3′),
4.61 (ddd, 1H, J2′ ,3′ = 4.9 Hz, J2′ ,1′ = 6.1 Hz, J2′ ,OH = 6.2 Hz, H2
′), 4.77 (br s, 2H, CH2), 5.15 (d, 1H,
JOH-3′ = 4.7 Hz, 3
′OH), 5.31 (dd, 1H, JOH-5′b = 6.9 Hz, JOH-5′a = 4.7 Hz, 5′OH), 5.41 (d, 1H, JOH-2′ = 6.2
Hz, 2′OH), 5.90 (d, 1H, J1′ ,2′ = 6.1 Hz, H1′), 7.11 (td, 1H, 3J5-6 = 7.5 Hz, 3J5-4 = 7.5 Hz, 4J5-3 = 1.0 Hz,
5JH-F < 1.0 Hz, 5H-2-F-Ph), 7.16 (ddd, 1H, 3JH-F = 9.4 Hz, 3J3-4 = 8.2 Hz, 4J3-5 = 1.0 Hz, 3H-2-F-Ph),
7.26 (dddd, 1H, 4JH-F = 5.5 Hz, 3J4-3 = 8.2 Hz, 3J4-5 = 7.5 Hz, 4J4-6 = 1.7 Hz, 4H-2-F-Ph), 7.32 (ddd,
1H, 4JH-F = 6.7 Hz, 3J6-5 = 7.5 Hz, 4J6-4 = 1.7 Hz, 6H-2-F-Ph), 8.21 (s, 2H, H2, NH), 8.39 (s, 1H, H8).
13C-NMR (100 MHz, DMSO-d6): δ = 36.78 (CH2), 61.62 (C5′), 70.60 (C3′), 73.49 (C2′), 85.86 (C4′), 87.92
(C1′), 114.95 (d, 2JC-F = 21.1 Hz, C3-Ph), 119.77 (C5), 124.18 (C5-Ph), 126.52 (d, 2JC-F = 12.6 Hz, C1-Ph),
128.52 (d, 3JC-F = 7.4 Hz, C4-Ph), 128.85 (br s, C6-Ph), 140.00 (C8), 148.59 (C4), 152.29 (C2), 154.49 (C6),
160.00 (d, 1JC-F = 244.0 Hz, C2-Ph). HRMS: m/z [M + H]+ calculated C17H19FN5O4+ 376.1416, found
376.1417; m/z [M + Na]+ calculated C17H18FN5O4Na+ 398.1235, found 398.1238.
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3.4. N6-(3-Fluorobenzyl)adenosine (6)
Following the procedure for the preparation of 5, the condensation of 4 (200 mg, 0.4 mmol)
with 3-fluorobenzylamine (0.091 mL, 0.8 mmol) in the presence of DIPEA (0.14 mL, 0.8 mmol) in
MeCN (3 mL) for 22 h at 70 ◦C with a subsequent deblocking in 8 M MeNH2 in EtOH solution
(4.5 mL) at room temperature gave 6 as a white powder. The overall yield was 111 mg (74%).
Rf 0.15 (CH2Cl2:EtOH—95:5). m.p. 159–160 ◦C. 1H-NMR (400 MHz, DMSO-d6): δ = 3.56 (ddd,
1H, J5′b,5′a = −12.0 Hz, J5′b,4′ = 3.4 Hz, J5′b,OH = 6.9 Hz, H5′b), 3.67 (ddd, 1H, J5′a,5′b = −12.0 Hz,
J5′a,4′ = 3.4 Hz, J5′a,OH = 4.7 Hz, H5
′a), 3.96 (q, 1H, J4′ ,5′b = 3.4 Hz, J4′ ,5′a = 3.4 Hz, J4′ ,3′ = 3.4 Hz,
H4′), 4.15 (td, 1H, J3′ ,4′ = 3.4 Hz, J3′ ,2′ = 4.7 Hz, J3′ ,OH = 4.7 Hz, H3′), 4.61 (ddd, 1H, J2′ ,3′ = 4.7 Hz,
J2′ ,1′ = 6.1 Hz, J2′ ,OH = 6.2 Hz, H2
′), 4.77 (br s, 2H, CH2), 5.15 (d, 1H, JOH-3′ = 4.7 Hz, 3′OH), 5.32 (dd, 1H,
JOH-5′b = 6.9 Hz, JOH-5′a = 4.7 Hz, 5
′OH), 5.41 (d, 1H, JOH-2′ = 6.2 Hz, 2′OH), 5.91 (d, 1H, J1′ ,2′ = 6.1 Hz,
H1′), 7.03 (dd, 1H, 3JH-F = 8.9 Hz, 3J4-5 = 8.2 Hz, 4H-3-F-Ph), 7.13 (d, 1H, 3JH-F = 8.9 Hz, 2H-3-F-Ph),
7.18 (dd, 1H, 3J6-5 = 8.2 Hz, 5JH-F = 2.2 Hz, 6H-3-F-Ph), 7.33 (td, 1H, 4JH-F = 6.3 Hz, 3J5-4 = 8.2 Hz,
3J5-6 = 8.2 Hz, 5H-3-F-Ph), 8.21 (s, 1H, H2 Ade), 8.39 (s, 1H, H8 Ade), 8.46 (br s, 1H, NH). 13C-NMR
(100 MHz, DMSO-d6): δ = 42.51 (CH2), 61.61 (C5′), 70.60 (C3′), 73.49 (C2′), 85.86 (C4′), 87.93 (C1′),
113.29 (d, 2JC-F = 21.0 Hz, C2-Ph), 113.71 (d, 2JC-F = 21.5 Hz, C4-Ph), 119.76 (C5), 123.06 (C6-Ph), 130.10
(d, 3JC-F = 7.5 Hz, C5-Ph), 139.99 (C8), 143.09 (br s, C1-Ph), 148.54 (C4), 152.30 (C2), 154.44 (C6), 162.16
(d, 1JC-F = 243.1 Hz, C3-Ph). HRMS: m/z [M + H]+ calculated C17H19FN5O4+ 376.1416, found 376.1418;
m/z [M + Na]+ calculated C17H18FN5O4Na+ 398.1235, found 398.1239.
3.5. N6-(4-Fluorobenzyl)adenosine (7)
Following the procedure for the preparation of 5, the condensation of 4 (200 mg, 0.4 mmol) with
4-fluorobenzylamine (0.091 mL, 0.8 mmol) in the presence of DIPEA (0.14 mL, 0.8 mmol) in MeCN
(3 mL) for 22 h at 70 ◦C with a subsequent deblocking in 8 M MeNH2 in EtOH solution (4.5 mL) at room
temperature gave 7 as a white powder. The overall yield was 81 mg (54%). Rf 0.15 (CH2Cl2:EtOH—95:5).
mp 181–182 ◦C. 1H-NMR (400 MHz, DMSO-d6): δ = 3.55 (ddd, 1H, J5′b,5′a = −12.0 Hz, J5′b,4′ = 3.4 Hz,
J5′b,OH = 6.9 Hz, H5
′b), 3.68 (ddd, 1H, J5′a,5′b = −12.0 Hz, J5′a,4′ = 3.4 Hz, J5′a,OH = 4.6 Hz, H5′a), 3.96
(q, 1H, J4′ ,5′b = 3.4 Hz, J4′ ,5′a = 3.4 Hz, J4′ ,3′ = 3.4 Hz, H4
′), 4.15 (ddd, 1H, J3′ ,4′ = 3.4 Hz, J3′ ,2′ = 4.7 Hz,
J3′ ,OH = 4.7 Hz, H3
′), 4.62 (ddd, 1H, J2′ ,3′ = 4.7 Hz, J2′ ,1′ = 6.1 Hz, J2′ ,OH = 6.2 Hz, H2′), 4.69 (br s, 2H,
CH2), 5.15 (d, 1H, JOH-3′ = 4.7 Hz, 3
′OH), 5.32 (dd, 1H, JOH-5′b = 6.9 Hz, JOH-5′a = 4.6 Hz, 5′OH), 5.41 (d,
1H, JOH-2′ = 6.2 Hz, 2
′OH), 5.89 (d, 1H, J1′ ,2′ = 6.1 Hz, H1′), 7.11 (t, 2H, 3JH-F = 8.9 Hz, 3J3-2 = 8.9 Hz,
3H-4-F-Ph, 5H-4-F-Ph), 7.37 (dd, 2H, 3J2-3 = 8.9, 4JH-F = 6.0 Hz, 2H-4-F-Ph, 6H-4-F-Ph), 8.21 (s, 1H,
H2 Ade), 8.37 (s, 1H, H8 Ade), 8.43 (br s, 1H, NH). 13C-NMR (100 MHz, DMSO-d6): δ = 42.21 (CH2),
61.62 (C5′), 70.61 (C3′), 73.48 (C2′), 85.87 (C4′), 87.93 (C1′), 114.87 (d, 2JC-F = 21.2 Hz, C3-Ph, C5-Ph),
119.74 (C5), 129.05 (d, 3JC-F = 7.5 Hz, C2-Ph, C6-Ph), 136.15 (C1-Ph), 139.91 (C8), 148.52 (C4), 152.30
(C2), 154.43 (C6), 161.07 (d, 1JC-F = 241.9 Hz, C4-Ph). HRMS: m/z [M + H]+ calculated C17H19FN5O4+
376.1416, found 376.1407; m/z [M + Na]+ calculated C17H18FN5O4Na+ 398.1235, found 398.1227.
3.6. N6-(2,6-Difluorobenzyl)adenosine (8)
Following the procedure for the preparation of 5, the condensation of 4 (191 mg, 0.384 mmol)
with 2,6-difluorobenzylamine (0.092 mL, 0.77 mmol) in the presence of DIPEA (0.134 mL, 0.77 mmol)
in MeCN (2.5 mL) for 11 h at 70 ◦C with a subsequent deblocking in 8 M MeNH2 in EtOH solution
(2 mL) at room temperature gave 8 as a white powder. The overall yield was 129 mg (85%).
Rf 0.15 (CH2Cl2:EtOH—95:5). m.p. 192–194 ◦C. 1H-NMR (400 MHz, DMSO-d6): δ = 3.56 (ddd,
1H, J5′b,5′a = −12.0 Hz, J5′b,4′ = 3.5 Hz, J5′b,OH = 6.8 Hz, H5′b), 3.68 (ddd, 1H, J5′a,5′b = −12.0 Hz,
J5′a,4′ = 3.5 Hz, J5′a,OH = 4.7 Hz, H5
′a), 3.97 (td, 1H, J4′ ,5′b = 3.5 Hz, J4′ ,5′a = 3.5 Hz, J4′ ,3′ = 3.3 Hz,
H4′), 4.15 (ddd, 1H, J3′ ,4′ = 3.3 Hz, J3′ ,2′ = 5.2 Hz, J3′ ,OH = 4.6 Hz, H3′), 4.61 (td, 1H, J2′ ,3′ = 5.2 Hz,
J2′ ,1′ = 6.1 Hz, J2′ ,OH = 6.1 Hz, H2
′), 4.80 (br s, 2H, CH2), 5.15 (d, 1H, JOH-3′ = 4.6 Hz, 3′OH), 5.31 (dd, 1H,
JOH-5′b = 7.0 Hz, JOH-5′a = 4.7 Hz, 5
′OH), 5.41 (d, 1H, JOH-2′ = 6.1 Hz, 2′OH), 5.89 (d, 1H, J1′ ,2′ = 6.1 Hz,
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H1′), 7.05 (dd, 2H, 3JH-F =7.6 Hz, Jm-H-p-H = 8.9 Hz, m-H-2,6-di-F-Ph), 7.37 (tt, 1H, Jp-H-m-H =8.9 Hz,
4JH-F = 6.0 Hz, p-H-2,6-di-F-Ph), 8.19 (br s, 1H, NH), 8.24 (s, 1H, H8 Ade), 8.36 (s, 1H, H2 Ade).
13C-NMR (100 MHz, DMSO-d6): δ = 32.17 (CH2), 61.61 (C5′), 70.59 (C3′), 73.50 (C2′), 85.83 (C4′), 87.93
(C1′), 111.38 (d, 2JC-F = 23.6 Hz, C3-Ph, C5-Ph), 114.44 (t, 2JC-F = 17.6 Hz, C1-Ph), 119.70 (C5), 129.60
(C4-Ph), 139.85 (C8), 148.64 (C4), 152.17 (C2), 154.16 (C6), 161.23 (d, 1JC-F = 248.0 Hz, C2-Ph, C6-Ph).
HRMS: m/z [M + H]+ calculated C17H18F2N5O4+ 394.1321, found 394.1325; m/z [M + Na]+ calculated
C17H17F2N5O4Na+ 416.1141, found 416.1143.
3.7. N6-(2-Trifluoromethylbenzyl)adenosine (9)
Following the procedure for the preparation of 5, the condensation of 4 (213 mg, 0.43 mmol) with
2-trifluoromethylbenzylamine (0.12 mL, 0.86 mmol) in the presence of DIPEA (0.15 mL, 0.86 mmol) in
MeCN (3 mL) for 10 h at 70 ◦C with a subsequent deblocking in 8 M MeNH2 in EtOH solution
(3 mL) at room temperature gave 9 as a white powder. The overall yield was 168 mg (92%).
Rf 0.13 (CH2Cl2:EtOH—95:5). m.p. 204–205 ◦C. 1H-NMR (400 MHz, DMSO-d6): δ = 3.56 (ddd,
1H, J5′b,5′a = −12.0 Hz, J5′b,4′ = 3.5 Hz, J5′b,OH = 6.9 Hz, H5′b), 3.68 (ddd, 1H, J5′a,5′b = −12.0 Hz,
J5′a,4′ = 3.5 Hz, J5′a,OH = 4.7 Hz, H5
′a), 3.97 (q, 1H, J4′ ,5′b = 3.5 Hz, J4′ ,5′a = 3.5 Hz, J4′ ,3′ = 3.5 Hz,
H4′), 4.16 (ddd, 1H, J3′ ,4′ = 3.5 Hz, J3′ ,2′ = 5.2 Hz, J3′ ,OH = 4.7 Hz, H3′), 4.63 (ddd, 1H, J2′ ,3′ = 5.2 Hz,
J2′ ,1′ = 6.1 Hz, J2′ ,OH = 6.2 Hz, H2
′), 4.93 (br s, 2H, CH2), 5.15 (d, 1H, JOH-3′ = 4.7 Hz, 3′OH), 5.29 (dd, 1H,
JOH-5′b = 6.9 Hz, JOH-5′a = 4.7 Hz, 5
′OH), 5.41 (d, 1H, JOH-2′ = 6.2 Hz, 2′OH), 5.91 (d, 1H, J1′ ,2′ = 6.1 Hz,
H1′), 7.40–7.75 (m, 4H, Ph), 8.19 (s, 1H, H8), 8.42 (s, 1H, H2), 8.45 (br s, 1H, NH). 13C-NMR (100 MHz,
DMSO-d6): δ = 39.52 (CH2, overlapping with the solvent peak), 61.62 (C5′), 70.62 (C3′), 73.51 (C2′),
85.89 (C4′), 87.92 (C1′), 119.83 (C5), 123.24 (C2 Ph), 125.77 (C6 Ph), 125.95 (q, JC-F = 30.7 Hz, CF3), 127.03
(C3 Ph), 127.54 (C4 Ph), 132.55 (C5 Ph), 138.10 (C1 Ph), 140.17 (C8), 146.68 (C4), 152.38 (C2), 154.52 (C6).
HRMS: m/z [M + H]+ calculated C18H19F3N5O4+ 426.1384, found 426.1387; m/z [M + Na]+ calculated
C18H18F3N5O4Na+ 448.1203, found 448.1210.
3.8. N6-(3-Trifluoromethylbenzyl)adenosine (10)
Following the procedure for the preparation of 5, the condensation of 4 (137 mg, 0.276 mmol) with
3-trifluoromethylbenzylamine (0.08 mL, 0.55 mmol) in the presence of DIPEA (0.096 mL, 0.55 mmol) in
MeCN (2 mL) for 20 h at 70 ◦C with a subsequent deblocking in 8 M MeNH2 in EtOH solution
(2 mL) at room temperature gave 10 as a white powder. The overall yield was 59 mg (50%).
Rf 0.11 (CH2Cl2:EtOH—95:5). m.p. 139–140 ◦C. 1H-NMR (400 MHz, DMSO-d6): δ = 3.55 (ddd,
1H, J5′b,5′a = −12.0 Hz, J5′b,4′ = 3.6 Hz, J5′b,OH = 7.0 Hz, H5′b), 3.68 (ddd, 1H, J5′a,5′b = −12.0 Hz,
J5′a,4′ = 3.6 Hz, J5′a,OH = 4.7 Hz, H5
′a), 3.97 (q, 1H, J4′ ,5′b = 3.6 Hz, J4′ ,5′a = 3.6 Hz, J4′ ,3′ = 3.6 Hz,
H4′), 4.16 (ddd, 1H, J3′ ,4′ = 3.6 Hz, J3′ ,2′ = 5.2 Hz, J3′ ,OH = 4.7 Hz, H3′), 4.62 (ddd, 1H, J2′ ,3′ = 5.2 Hz,
J2′ ,1′ = 6.1 Hz, J2′ ,OH = 6.2 Hz, H2
′), 4.80 (br s, 2H, CH2), 5.14 (d, 1H, JOH-3′ = 4.7 Hz, 3′OH), 5.30 (dd, 1H,
JOH-5′b = 7.0 Hz, JOH-5′a = 4.7 Hz, 5
′OH), 5.40 (d, 1H, JOH-2′ = 6.2 Hz, 2′OH), 5.90 (d, 1H, J1′ ,2′ = 6.1 Hz,
H1′), 7.5–7.75 (m, 4H, Ph), 8.21 (s, 1H, H8), 8.39 (s, 1H, H2), 8.53 (br s, 1H, NH). 13C-NMR (100 MHz,
DMSO-d6): δ = 42.60 (CH2), 61.63 (C5′), 70.63 (C3′), 73.54 (C2′), 85.89 (C4′), 87.97 (C1′), 119.79 (C5),
123.41 (C4 Ph), 123.69 (C2 Ph), 125.64 (C6 Ph), 128.96 (q, JC-F = 31.4 Hz, CF3), 129.30 (C5 Ph), 131.32 (C3
Ph), 140.08 (C8), 141.54 (C1 Ph), 148.58 (C4), 152.33 (C2), 154.43 (C6). HRMS: m/z [M + H]+ calculated
C18H19F3N5O4+ 426.1384, found 426.1384; m/z [M + Na]+ calculated C18H18F3N5O4Na+ 448.1203,
found 448.1204
3.9. N6-(4-Trifluoromethylbenzyl)adenosine (11)
Following the procedure for the preparation of 5, the condensation of 4 (190 mg, 0.382 mmol) with
4-trifluoromethylbenzylamine (0.11 mL, 0.76 mmol) in the presence of DIPEA (0.132 mL, 0.76 mmol) in
MeCN (3 mL) for 10 h at 70 ◦C with a subsequent deblocking in 8 M MeNH2 in EtOH solution
(3 mL) at room temperature gave 11 as a white powder. The overall yield was 160 mg (98%).
Rf 0.09 (CH2Cl2:EtOH—95:5). m.p. 152–153 ◦C. 1H-NMR (400 MHz, DMSO-d6): δ = 3.55 (ddd,
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1H, J5′b,5′a = −12.0 Hz, J5′b,4′ = 3.6 Hz, J5′b,OH = 6.9 Hz, H5′b), 3.68 (ddd, 1H, J5′a,5′b = −12.0 Hz,
J5′a,4′ = 3.6 Hz, J5′a,OH = 4.7 Hz, H5
′a), 3.97 (q, 1H, J4′ ,5′b = 3.6, J4′ ,5′a = 3.6 Hz, J4′ ,3′ = 3.6 Hz, H4′),
4.16 (ddd, 1H, J3′ ,4′ = 3.6 Hz, J3′ ,2′ = 5.2 Hz, J3′ ,OH = 4.7 Hz, H3
′), 4.62 (ddd, 1H, J2′ ,3′ = 5.2 Hz,
J2′ ,1′ = 6.1 Hz, J2′ ,OH = 6.2 Hz, H2
′), 4.80 (br s, 2H, CH2), 5.14 (d, 1H, JOH-3′ = 4.7 Hz, 3′OH), 5.30 (dd, 1H,
JOH-5′b = 6.9 Hz, JOH-5′a = 4.7 Hz, 5
′OH), 5.40 (d, 1H, JOH-2′ = 6.2 Hz, 2′OH), 5.90 (d, 1H, J1′ ,2′ = 6.1 Hz,
H1′), 7.5–7.75 (m, 4H, Ph), 8.20 (s, 1H, H8), 8.39 (s, 1H, H2), 8.51 (br s, 1H, NH). 13C-NMR (100 MHz,
DMSO-d6): δ = 42.65 (CH2), 61.60 (C5′), 70.59 (C3′), 73.49 (C2′), 85.86 (C4′), 87.91 (C1′), 119.79 (C5),
122.98 (C4 Ph), 125.07 (C3 Ph, C5 Ph), 127.48 (q, JC-F = 30.7 Hz, CF3), 127.67 (C2 Ph, C6 Ph), 140.02 (C8),
144.92 (C1 Ph), 148.59 (C4), 152.29 (C2), 154.42 (C6). HRMS: m/z [M + H]+ calculated C18H19F3N5O4+
426.1384, found 426.1383; m/z [M + Na]+ calculated C18H18F3N5O4Na+ 448.1203, found 448.1203.
3.10. Antiviral Assay Against EV71 in RD Cells
An EV71 BrCr laboratory-adapted strain was used at a low multiplicity of infection (MOI)
in a standardized antiviral assay [31]. Briefly, freshly harvested rhadbdosarcoma (RD) cells were
seeded in a 96-well plate (2 × 104 cells/well) and incubated at 37 ◦C in 5% CO2. The next day,
a serial dilution of the compounds was prepared in assay medium and added to the RD cells.
Then, the cells were supplemented with the viral suspension. The assay plates were incubated
until full virus–induced cell death was observed in the untreated, infected controls (3–4 days
post-infection). Subsequently, the antiviral effect was quantified using a colorimetric readout with
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium/phenazine
methosulfate (MTS/PMS method), and the concentration of compound at which a 50% inhibition of
virus-induced cell death would be observed (EC50) was calculated from the antiviral dose-response
curves. A similar assay setup was used to determine the adverse effect of the compound on uninfected,
treated cells for the calculation of the CC50 (concentration of compound that reduces overall cell health
with 50% as determined by the MTS/PMS method). The selectivity index (SI) was calculated as a ratio
of EC50/CC50.
4. Conclusions
We reported here the antiviral profile of a class of analogues of the cytokinin nucleoside BAPR,
previously described by our groups as a potent and selective inhibitor of EV71 replication. Interestingly,
we showed that the replacement of hydrogen with fluorine atoms or a trifluoromethyl group in
the aromatic moiety of BAPR overall increased its SI. In particular, the least successful analogue
(compound 7) with the addition of one fluorine atom at position 4 of the BAPR phenyl showed a
1.25-times increase of SI, whereas the best analogue of the class (compound 10) with a trifluoromethyl
at position 3 exhibited an SI that was 230 times higher than BAPR. Fluorinated analogues of
natural substances are of interest, since often the biological activity of the parent compounds is
improved. However, the tremendous gain in selectivity reported here represents one of the most
spectacular examples of structure optimization of a lead natural compound by introducing fluoro- or
trifluoromethyl groups into an aromatic moiety.
Supplementary Materials: Supplementary Materials are available online.
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